• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boston Scientific’s Eluvia drug-eluting stent succeeds in long lesions

November 6, 2018 By Sarah Faulkner

Boston ScientificBoston Scientific (NYSE:BSX) touted one-year data today from an analysis of its Eluvia drug-eluting vascular stent system, showing that the device is safe and effective in patients with long, complex, calcified lesions.

The data were presented by Boston Scientific at the annual Vascular Interventional Advances meeting.

The company’s Imperial trial included a 50-patient, single-arm analysis of Eluvia in people with femoropopliteal artery lesions 140-190 mm in length. These patients had an average lesion length of 162.8 mm, with 70% of lesions characterized as moderately to severely calcified and 32% with chronic total occlusions.

Following treatment with Boston Scientific’s Eluvia device, study participants had a primary patency rate of 87.9% and a target lesion revascularization rate of 6.5%. This sub-group of participants also reported experiencing improvements in their leg pain and discomfort, according to Boston Scientific.

“The lesion lengths, disease complexity and the baseline characteristics presented in this sub-study is more representative of what clinicians see on a daily basis when treating patients with severe cases of peripheral artery disease,” co-principal investigator Dr. William Gray said in prepared remarks.

“The results from this long lesion sub-study, combined with those observed in the global randomized controlled Imperial trial, Majestic and other studies suggest that the Eluvia stent, with its sustained drug release design, is a highly effective treatment option for femoropopliteal disease even in more complex lesion types,” Gray added.

“We are very pleased with the consistent clinical performance of the Eluvia drug-eluting stent across a broad spectrum of patient and lesion subtypes,” Dr. Ian Meredith, EVP & global CMO for Boston Scientific, said. “Without effective treatment options, patients with peripheral artery disease face the risk of developing permanent disability, potential amputation or even death which is why it is critical to ensure clinicians have access to therapies specifically developed to treat individuals suffering from this debilitating disease.”

Boston Scientific’s Eluvia stent is FDA-approved to treat long lesions within the superficial femoral and proximal popliteal arteries in patients with peripheral artery disease.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS